THOMAS, M. L., G. SHADDICK, R. CHARLTON, C. CAVILL, R. HOLLAND, F. IANNONE, G. LAPADULA, S. LOPRIORE, J. ZAVADA, Michal UHER, Karel PAVELKA, Lenka SZCZUKOVÁ, P. SIDIROPOULOS, I. FLOURI, A. DROSOS, B. MOLLER, M. J. NISSEN, R. B. MULLER, A. SCHERER, N. MCHUGH and A. NIGHTINGALE. Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. The Journal of Rheumatology. TORONTO: J RHEUMATOL PUBL CO, 2021, vol. 48, No 1, p. 48-57. ISSN 0315-162X. Available from: https://dx.doi.org/10.3899/jrheum.190815.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases
Authors THOMAS, M. L., G. SHADDICK, R. CHARLTON, C. CAVILL, R. HOLLAND, F. IANNONE, G. LAPADULA, S. LOPRIORE, J. ZAVADA, Michal UHER (203 Czech Republic, belonging to the institution), Karel PAVELKA (203 Czech Republic), Lenka SZCZUKOVÁ (203 Czech Republic, belonging to the institution), P. SIDIROPOULOS, I. FLOURI, A. DROSOS, B. MOLLER, M. J. NISSEN, R. B. MULLER, A. SCHERER, N. MCHUGH (guarantor) and A. NIGHTINGALE.
Edition The Journal of Rheumatology, TORONTO, J RHEUMATOL PUBL CO, 2021, 0315-162X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30226 Rheumatology
Country of publisher Canada
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.346
RIV identification code RIV/00216224:14110/21:00121692
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3899/jrheum.190815
UT WoS 000604916900009
Keywords in English comparative effectiveness; drug survival; methotrexate; psoriatic arthritis; TNF inhibitor
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/6/2021 12:55.
Abstract
Objective. To investigate whether tumor necrosis factor inhibitor ( TNFi) combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) is more effective for psoriatic arthritis (PsA) and/or improves TNFi drug survival compared to TNFi monotherapy. Methods. Five PsA biologics cohorts were investigated between 2000 and 2015: the ATTRA registry (Czech Republic); the Swiss Clinical Quality Management PsA registry; the Hellenic Registry of Biologics Therapies (Greece); the University of Bari PsA biologics database (Italy); and the Bath PsA cohort (UK). Drug persistence was analyzed using Kaplan-Meier and equality of survival using log-rank tests. Comparative effectiveness was investigated using logistic regression with propensity scores. Separate analyses were performed on (1) the combined Italian/Swiss cohorts for change in rate of Disease Activity Score in 28 joints (DAS28); and (2) the combined Italian, Swiss, and Bath cohorts for change in rate of Health Assessment Questionnaire (HAQ). Results. In total, 2294 patients were eligible for the drug survival analysis. In the Swiss (P = 0.002), Greek (P = 0.021), and Bath (P = 0.014) databases, patients starting TNFi in combination with methotrexate had longer drug survival compared to monotherapy, while in Italy the monotherapy group persisted longer (P = 0.030). In eligible patients from the combined Italian/Swiss dataset (n = 1056), there was no significant difference between treatment arms in rate of change of DAS28. Similarly, when also including the Bath cohort (n = 1205), there was no significant difference in rate of change of HAQ. Conclusion. Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.
PrintDisplayed: 24/5/2024 07:46